Structure Therapeutics (GPCR) Cash from Financing Activities (2022 - 2026)

Structure Therapeutics' Cash from Financing Activities history runs 5 years deep, the most recent figure standing at -$1.7 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 315.33% year-over-year to -$1.7 million; the TTM figure through Mar 2026 stood at $760.0 million (up 47.46% YoY), while the FY2025 annual figure was $762.5 million, up 47.99% from the prior year.
• Cash from Financing Activities was -$1.7 million for Q1 2026 at Structure Therapeutics, down from $705.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $705.0 million in Q4 2025 to a low of -$1.7 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged $103.3 million across 5 years, with a median of $615000.0 in 2024.
• The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities jumped 173400.67% in 2024, then tumbled 315.33% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at -$316000.0 in 2022, then surged by 89223.1% to $281.6 million in 2023, then slumped by 99.78% to $615000.0 in 2024, then surged by 114532.03% to $705.0 million in 2025, then slumped by 100.25% to -$1.7 million in 2026.
• The last three Cash from Financing Activities figures came in at -$1.7 million (Q1 2026), $705.0 million (Q4 2025), and $56.2 million (Q3 2025), per Business Quant data.